beta-Adrenoceptor blockade and pulmonary function in patients suffering from chronic obstructive lung disease

Area of Science:

• Pharmacology
• Pulmonology
• Clinical Medicine

Background:

• Beta-blockers can negatively impact pulmonary function.
• No beta-blocker is universally safe for patients with chronic obstructive lung disease (COPD).
• Alternative medications that do not affect lung function are often preferred.

Purpose of the Study:

• To review the effects of beta-blockers on pulmonary function.
• To identify patient groups at higher risk for beta-blocker-induced respiratory adverse effects.
• To compare the pulmonary safety profiles of different types of beta-blockers.

Main Methods:

• Literature review of studies on beta-blocker use in respiratory conditions.
• Analysis of the relationship between beta-blocker properties (ISA, selectivity) and pulmonary side effects.
• Clinical case analysis of patients with COPD and beta-blocker-related respiratory symptoms.

Main Results:

• Beta-blocker-induced pulmonary dysfunction is more common in patients with reversible airway obstruction (e.g., asthma, asthmatic bronchitis).
• Patients with irreversible obstruction (chronic bronchitis, emphysema) experience fewer relevant symptoms.
• Beta-blockers with intrinsic sympathomimetic activity (ISA) and beta 1-selective agents (e.g., pindolol) show a less pronounced effect on pulmonary function compared to non-selective agents (e.g., propranolol).

Conclusions:

• Caution is advised when prescribing beta-blockers to patients with COPD.
• Beta 1-selective blockers and those with ISA may offer a safer alternative.
• Combination therapy with beta-mimetic agents can mitigate adverse pulmonary effects, particularly with beta 1-selective blockade.